tbResList Print — ALC Acetyl-l-carnitine

Filters: qv=350, qv2=%, rfv=%

Product

ALC Acetyl-l-carnitine
Description: <b>Acetyl-L-carnitine (ALC or ALCAR)</b> is a naturally occurring molecule involved in mitochondrial energy metabolism.<br>
-ALC supports mitochondrial energy metabolism by transporting fatty acids into mitochondria.<br>
-Antioxidant effects: Reduces oxidative stress and lipid peroxidation.<br>
-In cancer patients with fatigue or cachexia (wasting), ALC can improve energy metabolism and physical function.<br>
-Acetyl-L-carnitine (ALC or ALCAR) levels are often reduced in Alzheimer's disease (AD) — especially in the brain and cerebrospinal fluid (CSF).<br>
-ALC is present at high concentrations in the brain<br>
-Carnitine is important in the β-oxidation of fatty acids and the acetyl portion can be used to maintain acetyl-CoA levels<br>
-ALC is active in cholinergic neurons, where it is involved in the production of acetylcholine<br>
-ALC significantly reduces Aβ-induced cytotoxicity, protein oxidation and lipid peroxidation in a concentration-dependent manner.<br>
-ALC can cause an increase in the level of ADAM10<br>

Pathway results for Effect on Cancer / Diseased Cells

Total Targets: 0

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress

ROS↓, 1,  

Cell Death

p‑Akt↑, 1,  

Proliferation, Differentiation & Cell State

PI3K↑, 1,  

Synaptic & Neurotransmission

ADAM10↑, 1,   BDNF↑, 1,  

Drug Metabolism & Resistance

Dose↝, 1,  

Functional Outcomes

cognitive↑, 3,   cognitive↝, 1,   Mood↑, 1,   Mood↝, 1,  
Total Targets: 10

Research papers

Year Title Authors PMID Link Flag
2025CarnitineNIHhttps://ods.od.nih.gov/factsheets/carnitine-HealthProfessional/0
2018Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease TreatmentRafaela PeronPMC5874708https://pmc.ncbi.nlm.nih.gov/articles/PMC5874708/0
2015Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in miceW. Wanghttps://www.sciencedirect.com/science/article/abs/pii/S03064522140099190
2003Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's diseaseStuart A Montgomery12598816https://pubmed.ncbi.nlm.nih.gov/12598816/0
2003Acetyl-L-carnitine for dementiaSheila A HudsonPMC6991156https://pmc.ncbi.nlm.nih.gov/articles/PMC6991156/0
2008Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot StudyRuth Remington, PhDhttps://journals.sagepub.com/doi/10.1177/15333175083250940